The development of effective and well-tolerated cancer therapies remains a major challenge. Experts from the Molecular Diagnostics Unit at the AIT Center for Health and Bioresources are identifying promising proteins that the immune system apparently recognises as "foreign" in colorectal cancer. These so-called tumour-associated antigens enable new approaches for therapeutic use. The cooperation with wings4innovation GmbH (w4i), the Austrian subsidiary of KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I), resulted in a particularly interesting first target, which now serves as the basis for the development of a specific therapeutic antibody.
2751 Characters
3 Images